Although we did not observe a differential expression in the levels of MLL2/KMT2D during the indolent chronic phase of our CML group compared to the control group, its expression was clearly reduced during the progression of the disease to accelerated phase and especially to the aggressive blast phase. The gene discussed is KMT2D; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.